Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06682-1 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Seval Beykan Schürrle und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Neuroendocrine Tumors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ipsen.
Abstract (Originalsprache)
Purpose
To evaluate the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [ 177 Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours (NETs).
Methods
This study was part of a phase I/II trial of [ 177 Lu]Lu-satoreotide tetraxetan, administered at a median cumulative activity of 13.0 GBq over three planned cycles (median activity/cycle: 4.5 GBq), in 40 patients with progressive NETs. Organ absorbed doses were monitored at each cycle using patient-specific dosimetry; the cumulative absorbed-dose limits were set at 23.0 Gy for the kidneys and 1.5 Gy for bone marrow. Absorbed dose coefficients (ADCs) were calculated using both patient-specific and model-based dosimetry for some patients.
Results
In all evaluated organs, maximum [ 177 Lu]Lu-satoreotide tetraxetan uptake was observed at the first imaging timepoint (4 h after injection), followed by an exponential decrease. Kidneys were the main route of elimination, with a cumulative excretion of 57–66% within 48 h following the first treatment cycle. At the first treatment cycle, [ 177 Lu]Lu-satoreotide tetraxetan showed a median terminal blood half-life of 127 h and median ADCs of [ 177 Lu]Lu-satoreotide tetraxetan were 5.0 Gy/GBq in tumours, 0.1 Gy/GBq in the bone marrow, 0.9 Gy/GBq in kidneys, 0.2 Gy/GBq in the liver and 0.8 Gy/GBq in the spleen. Using image-based dosimetry, the bone marrow and kidneys received median cumulative absorbed doses of 1.1 and 10.8 Gy, respectively, after three cycles. Conclusion [ 177 Lu]Lu-satoreotide tetraxetan showed a favourable dosimetry profile, with high and prolonged tumour uptake, supporting its acceptable safety profile and promising efficacy.
Trial registration
NCT02592707. Registered October 30, 2015.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
- CHU Nantes, Nantes Université, Médecine Nucléaire, Nantes, France.
- Department of Medical Imaging, CHU de Québec - Université Laval, Québec City, QC, Canada.
- Ipsen Innovation, Les Ulis, France.
- Department of Hepatology & Gastroenterology, ENETS Centre of Excellence, Aarhus University Hospital and Clinical Institute, Aarhus University, Aarhus, Denmark.
- Department of Radiology and Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Förderung
- Ipsen
Zitieren
APA
Schürrle, S. B., Eberlein, U., Ansquer, C., Beauregard, J. M., Durand-Gasselin, L., Grønbæk, H., Haug, A., Hicks, R. J., Lenzo, N. P., Navalkissoor, S., Nicolas, G. P., Pais, B., Volteau, M., Wild, D., McEwan, A., & Lassmann, M. (2024). Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06682-1
Vancouver
Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, et al. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06682-1
BibTeX
@article{Schrrle2024,
author = {Schürrle, Seval Beykan and Eberlein, Uta and Ansquer, Catherine and Beauregard, Jean-Mathieu and Durand-Gasselin, Lucie and Grønbæk, Henning and Haug, Alexander and Hicks, Rodney J and Lenzo, Nat P and Navalkissoor, Shaunak and Nicolas, Guillaume P and Pais, Ben and Volteau, Magali and Wild, Damian and McEwan, Alexander and Lassmann, Michael},
title = {Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06682-1}
}
EUVIMED